目的 探究十全大補(bǔ)丸聯(lián)合化療用于彌漫大B細(xì)胞淋巴瘤的臨床效果。方法 回顧性分析武漢大學(xué)人民醫(yī)院在2013年5月—2016年6月期間治療的彌漫大B細(xì)胞淋巴瘤患者152例作為該研究的對(duì)象，其中十全大補(bǔ)丸聯(lián)合化療的患者為觀察組80例，選擇常規(guī)的化療治療的患者為對(duì)照組72例，分別測(cè)定患者治療前、治療結(jié)束后的生活質(zhì)量、心臟功能、免疫功能、化療的不良反應(yīng)，并進(jìn)行對(duì)比分析，探究其療效。結(jié)果 觀察組患者完全緩解24例（30.00%），部分緩解30例（37.50%），總有效率67.50%，對(duì)照組完全緩解22例（30.55%），部分緩解28例（38.89%），總有效率（69.44%），差異無統(tǒng)計(jì)學(xué)意義。對(duì)照組患者的神經(jīng)毒性、肝功能異常、血小板降低、貧血、白細(xì)胞減少、乏力等的不良反應(yīng)的發(fā)生率和嚴(yán)重程度與觀察組的患者比較顯著較高，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療結(jié)束后，兩組患者的左心室射血分?jǐn)?shù)（LVEF）水平均有下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05），但組間比較差異并不明顯；兩組患者在治療前后B型腦鈉肽（BNP）和心肌肌鈣蛋白T（cTnT）無明顯變化。治療結(jié)束后，兩組患者CD4⁺/CD8⁺、自然殺傷（NK）細(xì)胞活性明顯改善（P<0.05），觀察組患者CD4⁺/CD8⁺、NK細(xì)胞活性略高于對(duì)照組，無統(tǒng)計(jì)學(xué)意義。對(duì)照組患者治療結(jié)束的生活質(zhì)量的改善率為52.77%，觀察組患者的生活質(zhì)量改善率為80.00%，治療后生活質(zhì)量明顯提升，且觀察組明顯優(yōu)于對(duì)照組，有統(tǒng)計(jì)學(xué)的意義（P<0.05）。結(jié)論 十全大補(bǔ)丸聯(lián)合化療用于彌漫大B細(xì)胞淋巴瘤，增強(qiáng)患者機(jī)體的免疫功能，可以減少化療過程對(duì)人體的帶來不良反應(yīng)，改善患者的生活質(zhì)量，值得臨床推廣。

Objective To explore the Shiquandabu Pill combined with chemotherapy in the clinical effect of diffuse large B-cell lymphoma. Methods Retrospective analysis of our hospital in May 2013 to June 2016 in the treatment of diffuse large B cell lymphoma in 152 patients as the object of the study. Shiquan Dabu Pill combined with chemotherapy for the observation group of 80 patients, the choice of conventional chemotherapy for the control group of 72 patients. The quality of life, cardiac function, immune function and adverse reactions of chemotherapy were measured before and after the treatment, and the curative effect was analyzed. Results In the observation group, 24 cases (30.00%) were completely relieved, 30 cases (37.50%) were partial remission, the total effective rate was 67.50%, the control group was completely relieved in 22 cases (30.55%), partial remission in 28 cases (38.89%), the total effective rate (69.44%), the difference was not statistically significant. The incidence and severity of adverse events such as neurotoxicity, abnormal liver function, thrombocytopenia, anemia, leukopenia, and fatigue in the control group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of LVEF were decreased in both groups (P < 0.05), but there was no significant difference between the two groups. There was no significant difference in BNP and cTnT between the two groups before and after treatment The After treatment, the activity of CD4⁺/CD8⁺ and NK cells in the observation group was significantly improved (P < 0.05). The activity of CD4⁺/CD8⁺ and NK cells in the observation group was slightly higher than that in the control group. The improvement rate of quality of life was 52.77% in the treatment group and 80.00% in the observation group. The quality of life was significantly improved after treatment, and the observation group was superior to the control group, which was statistically significant (P < 0.05). Conclusion Shiquan Dabu Pill combined with chemotherapy for diffuse large B-cell lymphoma, and enhance immune function in patients with the body, can reduce the course of chemotherapy adverse reactions to the human body to improve the quality of life of patients worthy of clinical promotion.